Brolucizumab
Brand names: Beovu · Active ingredient: Brolucizumab
In short: BEOVU® is indicated for the treatment of:
What is Brolucizumab used for?
BEOVU® is indicated for the treatment of:
Brolucizumab dosage
For ophthalmic intravitreal injection. BEOVU must be administered by a qualified physician.
BEOVU is available packaged as follows :
Pre-filled Syringe
Vial kit with injection components (vial, filter needle)
The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25 to 31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8 to 12 weeks.
The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks.
Store BEOVU in the refrigerator between 2°C to 8°C (36°F to 46°F); do not freeze. Keep BEOVU in the outer carton to protect from light.
Prior to use, the unopened glass vial or sealed blister pack of BEOVU may be kept at room temperature, 20°C to 25°C (68°F to 77°F) for up to 24 hours. After opening, proceed under aseptic conditions.
BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution.
BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the BEOVU must not be used.
Use aseptic technique for preparation of the intravitreal injection.
Pre-filled Syringe
The BEOVU pre-filled glass syringe is sterile and for the treatment of a single eye. It should be inspected visually prior to administration. Do not use if the packaging, or pre-filled syringe are opened, damaged, or expired .
STEP 1: PREPARE
Peel the lid off the blister package and, using aseptic technique, remove the sterile syringe.
STEP 2: SNAP OFF SYRINGE CAP
Snap off the syringe cap and dispose of it .
Do not turn or twist the syringe cap. | Figure 1:
STEP 3: ATTACH INJECTION NEEDLE
Aseptically and firmly assemble a 30-gauge x ½ inch sterile injection needle (not included) onto the Luer lock syringe.
STEP 4: DISLODGE AIR BUBBLES
To check for air bubbles, hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top .
Carefully remove the needle cap by pulling it straight off. | Figure 2:
STEP 5: EXPEL AIR AND SET THE DOSE
Hold the syringe at eye level and carefully push the plunger until the edge below the dome of the rubber stopper is aligned with the 0.05 mL dose mark . This will expel the air and the excess liquid and set the dose to the 0.05 mL dose mark. The syringe is ready for the injection. | Figure 3:
Vial
The BEOVU vial kit includes the sterile glass vial and filter needle which are sterile and for the treatment of a single eye. …
How to take Brolucizumab — instructions & advice from the label
Advise patients that in the days following BEOVU administration, patients are at risk of developing endophthalmitis, retinal detachment, retinal vasculitis and/or retinal vascular occlusion. If the eye becomes red, sensitive to light, painful, or if a patient develops any change in vision, instruct the patient to seek immediate care from an ophthalmologist .
Patients may experience temporary visual disturbances after an intravitreal injection with BEOVU and the associated eye examination . Advise patients not to drive or use machinery until visual function has recovered sufficiently.
Manufactured by:Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936U.S. License Number: 1244
© Novartis
T2024-60
Warnings & precautions
Do not take this medicine if: BEOVU is contraindicated in patients with ocular or periocular infections.
BEOVU is contraindicated in patients with active intraocular inflammation.
BEOVU is contraindicated in patients with known hypersensitivity to brolucizumab or any of the excipients in BEOVU. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment . Proper aseptic injection techniques must always be used when administering BEOVU. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately .
Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of BEOVU. These immune-mediated adverse events may occur following the first intravitreal injection. Discontinue treatment with BEOVU in patients who develop these events. Patients treated with BEOVU who experience intraocular inflammation may be at risk of developing retinal vasculitis and/or retinal vascular occlusion and should be closely monitored . Patients should be instructed to report any change in vision without delay.
Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection, including with BEOVU . Sustained IOP increases have also been reported. Both IOP and perfusion of the optic nerve head must be monitored and managed appropriately .
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the BEOVU clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. …
Brolucizumab side effects
The following potentially serious adverse reactions are described elsewhere in the labeling:
Hypersensitivity
Endophthalmitis and Retinal Detachment
Retinal Vasculitis and/or Retinal Vascular Occlusion
Increase in Intraocular Pressure
Thromboembolic Events
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
A total of 1,646 patients treated with brolucizumab constituted the safety population in four Phase 3 studies. Among these, 1,098 patients were treated with the recommended dose of 6 mg.
A total of 1,088 patients treated with brolucizumab, constituted the safety population in the two controlled neovascular AMD Phase 3 studies (HAWK and HARRIER) with a cumulative 96-week exposure to BEOVU, and 730 patients treated with the recommended dose of 6 mg . A total of 558 patients treated with brolucizumab constituted the safety population in the two controlled DME Phase 3 studies (KESTREL and KITE) from baseline to week 52, including 368 patients treated with the recommended dose of 6 mg .
aIncluding vision blurred, visual acuity reduced, visual acuity reduced transiently, and visual impairment. …
About this medicine
Brolucizumab-dbll is a recombinant human vascular endothelial growth factor inhibitor. Brolucizumab-dbll is a humanized monoclonal single-chain Fv (scFv) antibody fragment. Brolucizumab-dbll has a molecular weight of ~26 kilodaltons and is produced in Escherichia coli cells by recombinant DNA technology.
BEOVU (brolucizumab-dbll) injection is a sterile, clear to slightly opalescent, colorless to slightly brownish-yellow solution in a single-dose pre-filled syringe or a single-dose vial for intravitreal administration. Each single-dose pre-filled syringe and vial is designed to deliver 0.05 mL of solution containing 6 mg brolucizumab-dbll, polysorbate 80 (0.02%), sodium citrate (10 mM), sucrose (5.8%), and Water for Injection, USP and with a pH of approximately 7.2. This product does not contain an antimicrobial preservative.
How it works: Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d. Read the full official label on DailyMed.